DVA

Business profile & competitive position

DaVita Inc. operates in the Healthcare sector under the Medical - Care Facilities industry, and its core business is providing kidney dialysis services and related laboratory services for patients with chronic kidney failure and end-stage kidney disease. As of December 31, 2025, the company ran 2,657 outpatient dialysis centers in the United States serving approximately 200,500 patients, plus another 585 outpatient centers across 14 countries serving roughly 94,500 patients internationally. The U.S. dialysis segment alone generated approximately 86% of consolidated revenues, which makes DaVita a concentrated, scale player in renal care rather than a diversified healthcare conglomerate.

The financial signature of that position is mixed. The net margin of 6.0% is modest but positive, consistent with a service business that has pricing power with commercial payors but faces reimbursement pressure from government programs. The ROE figure of -123.6% is the outlier. A negative ROE of that magnitude is not an operational profit problem—DaVita is reporting earnings—but rather an accounting artifact typically created by a leveraged balance sheet or negative shareholders' equity. In other words, the denominator in return-on-equity has been compressed or inverted, which distorts the ratio even when the business itself is generating income. The beta of 0.83 also signals that the stock has historically moved less sharply than the overall market, fitting the defensive, healthcare-services profile. On the quality side, DaVita has led CMS's Quality Incentive Program for 11 of the most recently reported years and the Five-Star Quality Rating System for 10 of the most recently reported years, suggesting its competitive moat rests partly on operational consistency and regulatory quality scores.

Financial posture

DaVita currently carries an $11.4 billion market capitalization and trades at a P/E of 15.3. That valuation multiple sits in a middle range for a healthcare services company, neither deep-value nor aggressively growth-priced. The 6.0% net margin supports the idea of a steady, cash-generating service model, but the -123.6% ROE is a loud reminder that the capital structure, not the income statement, is what stands out on the equity-return metric.

Investors interpreting these numbers should separate profitability from leverage. The P/E of 15.3 tells you the market is putting a mid-teens multiple on earnings, while the negative ROE tells you equity has likely been reduced through debt, share repurchases, or accumulated losses in prior periods. The beta of 0.83 reinforces the view that DaVita behaves more like a defensive stock. Healthcare services companies with heavy fixed assets—dialysis centers, equipment, clinic leases—often carry meaningful debt, and DaVita's balance sheet appears to be no exception. Without taking a position on the stock, the posture is one of a leveraged, cash-flow-oriented services business trading at a moderate earnings multiple.

Strategic priorities & outlook

DaVita's most recent 10-K filing outlines three operational themes that define its near-term direction. First, the company wants to "reimagine" kidney care to be more preventative, better integrated, outcome-focused, lower-cost, and personalized at scale. Second, it is building integrated care capabilities that coordinate treatment from chronic kidney disease through end-stage kidney disease to kidney transplant. Third, it is aligning itself with the Comprehensive Kidney Care Contracting model, which aims to delay disease progression, promote home dialysis when clinically appropriate, and incentivize transplants.

Those priorities matter because they describe a business trying to move upstream in the disease continuum and capture value from better outcomes, not just higher treatment volume. Home dialysis and transplant support are lower-cost settings than in-center hemodialysis, so success here could affect both unit economics and regulatory relationships. The 10-K also notes that nearly all non-hospital dialysis profits come from commercial payors, even though U.S. dialysis provides the bulk of revenue. That commercial-payor dependence means the strategic push into integrated care is partly about defending and diversifying the payor mix, not just clinical quality.

Macro & geopolitical exposure

As a Medical - Care Facilities company, DaVita carries the classic macro exposures of a regulated healthcare services provider. The most direct risk is reimbursement policy: Medicare and Medicaid dialysis payment rates, which are set by CMS, heavily influence industry revenue even when commercial insurance provides the profit. Changes to the End-Stage Renal Disease payment bundle, quality incentive programs, or value-based care models like Comprehensive Kidney Care Contracting can shift margins quickly.

Beyond reimbursement, the sector is exposed to labor costs—nurses, technicians, and clinic staff—and to medical supply inflation, including dialyzers and pharmaceuticals used in treatment. The company's 585 international centers across 14 countries add currency translation risk and exposure to local healthcare regulation. Trade policy and supply-chain disruptions matter less directly than for manufacturers, but any restriction on imported medical equipment could affect clinic operations. Demographics are a long-term tailwind, since an aging population increases the incidence of chronic kidney disease, but that demand growth does not eliminate pricing or regulatory risk.

Recent developments

Recent headlines show DaVita has been attracting attention for both its momentum and its volatility. On October 2, 2026, Zacks published "DaVita HealthCare (DVA) Laps the Stock Market: Here's Why." Just days earlier, on September 29, 2026, The Motley Fool ran "This Warren Buffett Stock Is Up 58%. History Says This Is What Happens Next," highlighting DaVita's place in Berkshire Hathaway's portfolio and its strong year-to-date performance. On September 24, 2026, another Zacks article noted that "DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note," and on September 21, 2026, MarketBeat included it among "3 Surging Stocks That Don't Need the AI Boom to Keep Winning."

Taken together, these headlines illustrate a stock that has become a non-AI, Buffett-backed healthcare story with both followers and skeptics. The near-simultaneous positive and cautionary Zacks articles underscore that the recent price action has been headline-sensitive and that momentum can reverse quickly even without a fundamental re-rating.

Earnings behavior & post-earnings drift

DaVita has beaten earnings estimates in 6 of the last 8 reported quarters, a 75% beat rate, with an average earnings surprise of 2.3%. Across those quarters, the average 5-day price move after earnings has been +6.36%, classified as an upward drift. At first glance, that looks like a stock that rewards positive surprises. The reality is more complicated.

Over the last four reported quarters, the relationship between beats and price action has been inconsistent. On August 4, 2026, DaVita reported EPS of $4.02 against an estimate of $3.88, a 3.6% positive surprise, yet the stock fell 17.24% the next day and 21.78% over the following five days. By contrast, the May 5, 2026 quarter delivered EPS of $2.87 versus $2.41 estimated, a 19.1% beat, and the stock jumped 23.46% the next day and 27.7% over five days. The February 2, 2026 report showed EPS of $3.40 against $3.24 estimated, a 4.9% beat, driving a 21.17% one-day gain and a 23.79% five-day gain. The October 29, 2025 quarter was a miss—actual EPS of $2.51 versus $3.17 estimated, a -20.8% surprise—and the stock fell 6.17% the next day and 4.27% over five days, which was actually a smaller drawdown than the August beat produced.

The takeaway is that beats have not reliably produced continued upside in DaVita. The August 2026 reaction is the clearest example: a modest beat triggered a severe selloff, likely because the unofficial consensus or forward guidance embedded in the price was much higher than the reported number. With the next earnings report scheduled for November 4, 2026 after the close and the consensus EPS estimate at $3.55, traders should remember that the headline surprise is only one input; how the market has already positioned itself, and what management says about the outlook, can override the beat itself. The current price of $178.265 sits below the 50-day EMA of $187.16, with an RSI of 45.1, suggesting the stock is in a neutral-to-weak short-term posture heading into that report.

For a deeper dive into how institutional analysts are currently sizing up DaVita's earnings setup, valuation, and forward estimates, readers should review the full institutional verdict on the platform.